Erika Jean Stromberg

TL;DR: The demonstrated feasibility to manufacture a single recombinant vaccine comprising multiple protective open reading frames and the potential use of MPL-SE as a substitute for IL-12, takes us closer to the realization of an affordable and safe Leishmania vaccine.

TL;DR: Immunization of BALB/c mice with recombinant TSA protein resulted in the development of strong cellular immune responses and conferred protective immune responses against infection with L. major, suggesting that the TSA protein may be useful as a component of a subunit vaccine against leishmaniasis.

TL;DR: IFN-γ enzyme-linked immunospot analysis demonstrated the presence of T cells specific for several of these Ags in PBMC from self-healing cutaneous leishmaniasis patients infected with either Leishmania tropica or L. major.

TL;DR: In this article, compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed, which include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polyptides.